Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defibrotide for Severe Hepatic VOD in HSCT Patients
NCT00003966Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Apr 2000
- Primary completion
- Feb 2006
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of defibrotide in hepatic veno-occlusive disease (HVOD) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Complete Response Rate at 60 days. Started Apr 2000; status: completed.
02
Drugs
defibrotide
03
Conditions
hepatic veno-occlusive disease (HVOD)
Beyond the preview
Go deeper on NCT00003966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003966.